US Oral Contraceptive OTC Switch Sponsor Says ‘Challenging Target’ Met For Adolescents In Study

HRA executives and other representatives for firm and FDA officials will make presentations about HRA’s sNDA to agency’s Nonprescription Drug and Obstetrics, Reproductive and Urologic Drugs advisory committees during a joint meeting on 9-10 May.

• Source: Shutterstock

HRA Pharma spares no detail on the benefits of allowing adolescent access in the information it provided to an advisory panel recommending whether the Food and Drug Administration should approve its proposal for the first Rx-to-OTC switch of a daily oral contraceptive in the US.

The Perrigo Company PLC subsidiary also counters FDA concerns about the numbers of adolescent and of low healthy literacy...

More from Regulation

More from Policy & Regulation